Comparative evaluation of Allplex HPV28 and Anyplex II HPV28 assays for high-risk HPV genotyping in cervical samples
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0320978 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Sarah Mafi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology, Virology and Hygiene, CHU Limoges, Limoges, France. Hauptthemen laut MEDLINE: Papillomavirus Infections, Uterine Cervical Neoplasms, Papillomaviridae, Cervix Uteri. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seegene.
Abstract (Originalsprache)
Background/Objectives Human papillomavirus (HPV) genotyping is essential for cervical cancer screening and prevention. The Allplex TM HPV28 real-time PCR kit, using different chemistry and results analysis compared with its predecessor, the Anyplex TM II HPV28 kit, has recently been launched. This study aims to compare the Allplex TM HPV28 and Anyplex TM II HPV28 assays in detecting and genotyping the 13 high-risk (HR)-HPV types. Study design Between 2022 and 2023, 459 cervical samples from women undergoing cervical cancer screening were selected. These samples were analysed by liquid-based cytology and tested by both kits concurrently.
Results
Allplex TM HPV28 Ct values correlated well with Anyplex TM II HPV28 signal intensity scores. No significant differences between assays were observed in overall and genotype-specific HR-HPV prevalence determined in all samples and according to cytological results. In addition, no significant differences were identified between assays in the detection of single and multiple HR-HPV infections. Most of the discordant results corresponded to samples showing weak HR-HPV signals and multiple HR-HPV types.
Conclusions
Our results demonstrate that the Allplex TM HPV28 kit can be used for HPV genotyping, with results overall similar to those obtained with the Anyplex TM II HPV28 kit and the addition of Ct values for patient follow-up. The clinical implications of the potentially reduced sensitivity of the Allplex TM HPV28 kit in detecting HPV31 ( p = 0.07) and HPV39 ( p = 0.08) warrant further investigation in subsequent studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bacteriology, Virology and Hygiene, CHU Limoges, Limoges, France.
- University of Limoges, INSERM, RESINFIT, U1092, Limoges, France.
- Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France.
ORCID-Profile: Sarah Mafi, Sylvain Meyer, Marine Dupont
Förderung
- Seegene
Zitieren
APA
Mafi, S., Theuillon, F., Meyer, S., Woillard, J. B., Dupont, M., Rogez, S., Alain, S., & Hantz, S. (2025). Comparative evaluation of Allplex HPV28 and Anyplex II HPV28 assays for high-risk HPV genotyping in cervical samples. PLOS ONE. https://doi.org/10.1371/journal.pone.0320978
Vancouver
Mafi S, Theuillon F, Meyer S, Woillard JB, Dupont M, Rogez S, et al. Comparative evaluation of Allplex HPV28 and Anyplex II HPV28 assays for high-risk HPV genotyping in cervical samples. PLOS ONE. 2025. doi:10.1371/journal.pone.0320978
BibTeX
@article{Mafi2025,
author = {Mafi, Sarah and Theuillon, Flavie and Meyer, Sylvain and Woillard, Jean-Baptiste and Dupont, Marine and Rogez, Sylvie and Alain, Sophie and Hantz, Sébastien},
title = {Comparative evaluation of Allplex HPV28 and Anyplex II HPV28 assays for high-risk HPV genotyping in cervical samples},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0320978}
}
EUVIMED